RIBOMIC Inc. is a listed company. Its directors and officers file their transactions with EDINET (Japan FSA). Over the twelve months to 18 October 2026, the company's managers filed 9 filings, from 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
With 9 filings in twelve months, the company is more active than the median of 3 filings across the 3,419 companies we follow on the same exchange.
There has been no open-market purchase by an insider of RIBOMIC Inc. for at least a year. Typically, a trade is published a median of 7 days after it takes place. That lag is the time during which only the insider knows about the trade.
Source: insider filings from EDINET (Japan FSA). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended March 2026 · cache
25 of 25 declarations
Ribomic Inc. is a Japanese company listed on the XTKS market, specializing in the development of drugs based on ribozyme technology. It focuses on innovative treatments for various diseases.